OxRML/AgentSLR huggingface dataset:
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 57 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 35 - 74 (95% CI)
Case definition: Lab confirmed
Numerator/denominator:  / 574 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Estimated model parameter
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Laranjeiras
Setting: Other, 
Sample size: 574
Study period: Jul 2016 - Jun 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 30 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 17 - 46 (95% CI)
Case definition: Lab confirmed
Numerator/denominator:  / 345 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Estimated model parameter
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Fortaleza
Setting: Other, 
Sample size: 345
Study period: Jul 2016 - Jun 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 47 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 25 - 69 (95% CI)
Case definition: Lab confirmed
Numerator/denominator:  / 1110 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Estimated model parameter
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Recife
Setting: Other, 
Sample size: 1110
Study period: Jul 2016 - Jun 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 40 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 30 - 72 (95% CI)
Case definition: Lab confirmed
Numerator/denominator:  / 1017 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Estimated model parameter
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Cuiaba and Campo Grande
Setting: Other, 
Sample size: 1017
Study period: Jul 2016 - Jun 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 15 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 4 - 29 (95% CI)
Case definition: Lab confirmed
Numerator/denominator:  / 751 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Estimated model parameter
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Porto Velho
Setting: Other, 
Sample size: 751
Study period: Jul 2016 - Jun 2019
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 1.28 No units ()
Exponent (base 10): 0
Uncertainty: 1.08 - 1.69 (95% CI)
Statistical approach: Estimated model parameter
Reproduction number method: Other Unspecified
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Belo Horizonte
Setting: Other, 
Sample size: 817
Study period: Jul 2016 - Jun 2016
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 1.41 No units ()
Exponent (base 10): 0
Uncertainty: 1.12 - 2.08 (95% CI)
Statistical approach: Estimated model parameter
Reproduction number method: Other Unspecified
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Salvador, Bahia
Setting: Other, 
Sample size: 494
Study period: Jul 2016 - Jun 2019
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 2.33 No units ()
Exponent (base 10): 0
Uncertainty: 1.54 - 3.85 (95% CI)
Statistical approach: Estimated model parameter
Reproduction number method: Other Unspecified
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Laranjeiras
Setting: Other, 
Sample size: 574
Study period: Jul 2016 - Jun 2019
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 1.43 No units ()
Exponent (base 10): 0
Uncertainty: 1.21 - 1.85 (95% CI)
Statistical approach: Estimated model parameter
Reproduction number method: Other Unspecified
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Fortaleza
Setting: Other, 
Sample size: 345
Study period: Jul 2016 - Jun 2019
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 1.89 No units ()
Exponent (base 10): 0
Uncertainty: 1.33 - 3.23 (95% CI)
Statistical approach: Estimated model parameter
Reproduction number method: Other Unspecified
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Recife
Setting: Other, 
Sample size: 1110
Study period: Jul 2016 - Jun 2019
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 1.67 No units ()
Exponent (base 10): 0
Uncertainty: 1.43 - 3.57 (95% CI)
Statistical approach: Estimated model parameter
Reproduction number method: Other Unspecified
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Cuiaba and Campo Grande
Setting: Other, 
Sample size: 1017
Study period: Jul 2016 - Jun 2019
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 1.18 No units ()
Exponent (base 10): 0
Uncertainty: 1.04 - 1.41 (95% CI)
Statistical approach: Estimated model parameter
Reproduction number method: Other Unspecified
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Porto Velho
Setting: Other, 
Sample size: 751
Study period: Jul 2016 - Jun 2019
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 0.5477 No units (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Compartmental model Vector-human
Trimester exposed: Unspecified
Population: Unspecified, sex: Unspecified, ages  to 
Country: Colombia
Setting: Unspecified, Unspecified
Study period: 2016
Parameter: Human delay - incubation period (inverse parameter) (Human delay)
Value: 0.0686 Per day (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Trimester exposed: Unspecified
Population: Unspecified, sex: Unspecified, ages  to 
Country: Colombia
Setting: Unspecified, Unspecified
Study period: 2016
Parameter: Human delay - infectious period (inverse parameter) (Human delay)
Value: 0.0228 Per day (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Trimester exposed: Unspecified
Population: Unspecified, sex: Unspecified, ages  to 
Country: Colombia
Setting: Unspecified, Unspecified
Study period: 2016
Parameter: Human delay - Recovery/non-Infectiousness to Susceptibility (inverse parameter) (Human delay)
Value: 0.054 Per day (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Trimester exposed: Unspecified
Population: Unspecified, sex: Unspecified, ages  to 
Country: Colombia
Setting: Unspecified, Unspecified
Study period: 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 2.18 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Confirmed;Lab confirmed
Numerator/denominator: 277 / 12374 (method: )
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Mixed groups, sex: Unspecified, ages  to 
Country: United States
Location: Hidalgo County, Texas
Setting: Hospital based, Unspecified
Sample size: 12374
Study period: 2016 - 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 18.8 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Confirmed;Lab confirmed
Numerator/denominator: 44 / 234 (method: )
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Mixed groups, sex: Unspecified, ages  to 
Country: United States
Location: Hidalgo County, Texas
Setting: Hospital based, Unspecified
Sample size: 234
Study period: 2016 - 2018
Parameter: Attack rate (Attack rate)
Value: 50 Percentage (%) (Unspecified)
Exponent (base 10): 0
Uncertainty: 43 - 58 (95% CrI)
Statistical approach: Estimated model parameter
Population: Mixed groups, sex: Both, ages  to 
Country: France
Location: Martinique
Setting: Mixed settings, 
Study period: 2015 - 2016
Parameter: Human delay - incubation period (Human delay)
Value: 4.9 Days (Mean)
Exponent (base 10): 0
Uncertainty: 4.59 - 5.21 (95% CI)
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Both, ages 4 to 90
Country: India
Location: Jaipur, Rajasthan
Setting: Population based, Urban area
Sample size: 111
Study period: 22 Sep 2018 - 16 Nov 2018
Parameter: Human delay - incubation period (Human delay)
Value: 6 Days (Median)
Exponent (base 10): 0
Uncertainty: 2 - 10 (Range)
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Both, ages 4 to 90
Country: India
Location: Jaipur, Rajasthan
Setting: Population based, Urban area
Sample size: 111
Study period: 22 Sep 2018 - 16 Nov 2018
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 2.2798 No units ()
Exponent (base 10): 0
Bounds: 2.1062 - 2.4443
Statistical approach: Estimated model parameter
Reproduction number method: Compartmental model Vector-human
Population: General population, sex: Unspecified, ages  to 
Country: United States
Location: Puerto Rico
Setting: Unspecified, Unspecified
Sample size: 3681000
Study period: Dec 2015 - Dec 2016
Parameter: Reproduction number (Effective, Re) (Reproduction number)
Value:  No units ()
Exponent (base 10): 0
Bounds: 0 - 3.1
Statistical approach: Estimated model parameter
Disaggregated by: Time
Reproduction number method: Compartmental model Vector-human
Population: General population, sex: Unspecified, ages  to 
Country: United States
Location: Puerto Rico
Setting: Unspecified, Unspecified
Sample size: 3681000
Study period: Dec 2015 - Dec 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 13.7 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 9.4 - 19.14 (95% CI)
Statistical approach: Observed sample statistic
Disaggregated by: Age, Sex
Population: , sex: Both, ages 2 to 29
Country: Senegal
Location: Niakhar
Setting: , Unspecified
Study period: Nov 2011 - Apr 2012
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 7.1 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 4.03 - 11.45 (95% CI)
Statistical approach: Observed sample statistic
Disaggregated by: Age, Sex
Population: , sex: Both, ages 2 to 29
Country: The Gambia
Location: Basse Santa Su
Setting: , Unspecified
Study period: Nov 2011 - Apr 2012
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0.3 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 0.01 - 1.9 (95% CI)
Statistical approach: Observed sample statistic
Disaggregated by: Age, Sex
Population: , sex: Both, ages 2 to 29
Country: Mali
Location: Bamako
Setting: , Unspecified
Study period: Aug 2007 - Oct 2007
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 13.4 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 9.65 - 17.9 (95% CI)
Statistical approach: Observed sample statistic
Disaggregated by: Age, Sex
Population: , sex: Both, ages 2 to 29
Country: Senegal
Location: Niakhar
Setting: , Unspecified
Study period: Aug 2007 - Oct 2007
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 3.7 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 1.87 - 6.55 (95% CI)
Statistical approach: Observed sample statistic
Disaggregated by: Age, Sex
Population: , sex: Both, ages 2 to 29
Country: The Gambia
Location: Basse Santa Su
Setting: , Unspecified
Study period: Aug 2007 - Oct 2007
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0.4 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 0.01 - 2.42 (95% CI)
Statistical approach: Observed sample statistic
Disaggregated by: Age, Sex
Population: , sex: Both, ages 2 to 29
Country: Mali
Location: Bamako
Setting: , Unspecified
Study period: Nov 2011 - Apr 2012
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 2.3 Percentage (%) (Mean)
Exponent (base 10): 0
Numerator/denominator:  / 176 (method: )
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Vietnam
Location: Ho Chi Minh City
Setting: Hospital based, 
Sample size: 176
Study period: Jan 2008 - Dec 2008
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 5.7 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Blood donors, sex: Both, ages 18 to 63
Country: Republic of the Congo
Location: Brazzaville, Pointe-Noire, Ewo, Gamboma, Oyo, Owando
Setting: Other, Both urban and rural areas
Sample size: 386
Study period: Mar 2011 - Jul 2011
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 1.8 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Blood donors, sex: Both, ages 18 to 63
Country: Republic of the Congo
Location: Brazzaville, Pointe-Noire, Ewo, Gamboma, Oyo, Owando
Setting: Other, Both urban and rural
Sample size: 386
Study period: Mar 2011 - Jul 2011
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 1.1 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Blood donors, sex: , ages  to 
Country: Republic of the Congo
Location: Brazzaville
Setting: Other, Urban
Study period: Mar 2011 - Jul 2011
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 3.2 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Blood donors, sex: , ages  to 
Country: Republic of the Congo
Location: Pointe-Noir
Setting: Other, Urban
Study period: Mar 2011 - Jul 2011
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 94 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 176 / 187 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Nicaragua
Location: León
Setting: Hospital based, 
Sample size: 187
Study period: Feb 2017 - Jul 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 61 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 107 / 176 (method: Adjusted)
Seroprevalence adjustment: Adjusted
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Nicaragua
Location: León
Setting: Hospital based, 
Sample size: 176
Study period: Feb 2017 - Jul 2017
Parameter: Seroprevalence - IFA (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 5 / 196 (method: Naive)
Seroprevalence adjustment: Naive
Population: General population, sex: Both, ages  to 
Country: Hungary
Setting: Travel based, Unspecified
Sample size: 196
Study period: 2016
Parameter: Seroprevalence - IFA (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 1 / 219 (method: Naive)
Seroprevalence adjustment: Naive
Population: General population, sex: Both, ages  to 
Country: Hungary
Setting: Travel based, Unspecified
Sample size: 219
Study period: 2017
Parameter: Seroprevalence - IFA (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 1 / 188 (method: Naive)
Seroprevalence adjustment: Naive
Population: General population, sex: Both, ages  to 
Country: Hungary
Setting: Travel based, Unspecified
Sample size: 188
Study period: 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 30.4 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 290 / 955 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Both, ages 5 to 12
Country: Thailand
Location: Ratchaburi, Bangkok
Setting: School based, Both urban and rural areas
Sample size: 955
Study period: 2006 - 2009
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 2.4 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 1 / 41 (method: naïve)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Female, ages 15 to 39
Country: Brazil
Location: Fortaleza
Setting: Community based, 
Sample size: 1289
Study period: Feb 2018 - Dec 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 4 / 29 (method: Adjusted)
Seroprevalence adjustment: Unspecified
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: India
Setting: Unspecified, 
Sample size: 29
Study period: May 2021 - Oct 2021
Parameter: Seroprevalence - NS1 BOB ELISA (Seroprevalence)
Value: 7.6 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 6.1 - 9.3 (95% CI)
Case definition: Lab confirmed
Numerator/denominator: 82 / 1085 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age, Other, Sex
Population: Mixed groups, sex: Both, ages  to 
Country: Malaysia
Location: Kuala Lumpur
Setting: Mixed settings, Urban area
Sample size: 1085
Study period: 2012 - 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 3.3 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 2.4 - 4.6 (95% CI)
Case definition: Lab confirmed
Numerator/denominator: 36 / 82 (method: Adjusted)
Seroprevalence adjustment: Adjusted
Statistical approach: Observed sample statistic
Population: Mixed groups, sex: Both, ages  to 
Country: Malaysia
Location: Kuala Lumpur
Setting: Mixed settings, Urban area
Sample size: 1085
Study period: 2012 - 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 64.9 Percentage (%) ()
Exponent (base 10): 0
Bounds: 64.9 - 82.3
Case definition: Lab confirmed
Numerator/denominator: 213 / 328 (method: naïve)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Method
Population: Mixed groups, sex: Both, ages 16 to 47
Country: Colombia
Location: Santander
Setting: School based, 
Sample size: 328
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 31.5 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 314 / 997 (method: Adjusted)
Seroprevalence adjustment: Adjusted
Statistical approach: Estimated model parameter
Population: Persons under investigation, sex: Both, ages  to 
Country: Philippines
Setting: Population based, Both urban and rural areas
Sample size: 997
Study period: 2016
Parameter: Attack rate (Attack rate)
Value: 5.5 Percentage (%) (Mean)
Exponent (base 10): 0
Uncertainty: 3 - 10.4 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: Both, ages  to 
Country: Philippines
Setting: Population based, Both urban and rural areas
Sample size: 997
Study period: 2016
Parameter: Human delay - latent period (inverse parameter) (Human delay)
Value: 0.0686 Per day (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Trimester exposed: Unspecified
Population: Unspecified, sex: Unspecified, ages  to 
Country: Colombia
Setting: Unspecified, Unspecified
Study period: Unspecified
Parameter: Human delay - infectious period (inverse parameter) (Human delay)
Value: 0.0228 Per day (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Trimester exposed: Unspecified
Population: Unspecified, sex: Unspecified, ages  to 
Country: Unspecified
Setting: Unspecified, Unspecified
Study period: Unspecified
Parameter: Human delay - Recovery/non-Infectiousness to Susceptibility (inverse parameter) (Human delay)
Value: 0.054 Per day (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Trimester exposed: Unspecified
Population: Unspecified, sex: Unspecified, ages  to 
Country: Unspecified
Setting: Unspecified, Unspecified
Study period: Unspecified
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 10 Percentage (%) (Mean)
Exponent (base 10): 0
Uncertainty: 3.8 - 20.1 (95% CI)
Case definition: Lab confirmed
Numerator/denominator: 10 / 100 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages 1 to 78
Country: Nigeria
Location: Cross River State
Setting: Population based, Both urban and rural areas
Sample size: 100
Study period: 17 Mar 2017 - 30 May 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 12 Percentage (%) (Mean)
Exponent (base 10): 0
Uncertainty: 9.9 - 14.4 (95% CI)
Case definition: Lab confirmed
Numerator/denominator: 12 / 100 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages 1 to 78
Country: Nigeria
Location: Cross River State
Setting: Population based, Both urban and rural areas
Sample size: 100
Study period: 17 Mar 2017 - 30 May 2017
Parameter: Seroprevalence - IgG and IgM (Seroprevalence)
Value: 20 Percentage (%) (Mean)
Exponent (base 10): 0
Uncertainty: 11.9 - 30.2 (95% CI)
Case definition: Lab confirmed
Numerator/denominator: 20 / 100 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages 1 to 78
Country: Nigeria
Location: Cross River State
Setting: Population based, Both urban and rural areas
Sample size: 100
Study period: 17 Mar 2017 - 30 May 2017
Parameter: Mosquito delay - extrinsic incubation period (Mosquito)
Value: 8.88 Days (Mean)
Exponent (base 10): 0
Uncertainty: 8 - 10 (95% CrI)
Statistical approach: Estimated model parameter
Population: Other, sex: Unspecified, ages  to 
Country: Unspecified
Setting: Unspecified, 
Study period: Unspecified
Parameter: Mosquito delay - extrinsic incubation period (Mosquito)
Value: 7.33 Days (Mean)
Exponent (base 10): 0
Uncertainty: 6 - 9 (95% CrI)
Statistical approach: Estimated model parameter
Population: Other, sex: Unspecified, ages  to 
Country: Unspecified
Setting: Unspecified, 
Study period: Unspecified
Parameter: Reproduction number (Basic R0) - Vector-borne (Reproduction number)
Value: 2.96 No units (Mean)
Exponent (base 10): 0
Uncertainty: 2.58 - 3.39 (95% CrI)
Statistical approach: Estimated model parameter
Reproduction number method: Ross-Macdonald formula Vector-human
Population: Other, sex: Unspecified, ages  to 
Country: Unspecified
Setting: Unspecified, 
Study period: Unspecified
Parameter: Reproduction number (Basic R0) - Vector-borne (Reproduction number)
Value: 4.05 No units (Mean)
Exponent (base 10): 0
Uncertainty: 3.22 - 5.17 (95% CrI)
Statistical approach: Estimated model parameter
Reproduction number method: Ross-Macdonald formula Vector-human
Population: Other, sex: Unspecified, ages  to 
Country: Unspecified
Setting: Unspecified, 
Study period: Unspecified
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 10.3 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 83 / 801 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age, Other
Population: Mixed groups, sex: Both, ages  to 60
Country: Vietnam
Location: Krong Buk
Setting: Community based, 
Sample size: 801
Study period: Jan 2017 - Jul 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 1.1 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 9 / 83 (method: Adjusted)
Seroprevalence adjustment: Adjusted
Statistical approach: Observed sample statistic
Disaggregated by: Age, Other
Population: Mixed groups, sex: Both, ages  to 60
Country: Vietnam
Location: Krong Buk
Setting: Community based, 
Sample size: 801
Study period: Jan 2017 - Jul 2018
Parameter: Mutations - evolutionary rate (Mutations)
Value: 8.65 Substitutions/site/year (Central)
Exponent (base 10): -4
Statistical approach: Estimated model parameter
Genome site: Whole genome sequence
Genomic lineage: Asian lineage
Population: Unspecified, sex: , ages  to 
Country: Multi-country: Americas, Oceania
Location: Americas and Oceania
Setting: Unspecified, Unspecified
Sample size: 360
Study period: Unspecified